Breast cancer is one of the leading oncological diseases worldwide and the most frequently diagnosed malignancy among women. Its high incidence, together with the progressive improvement in early diagnosis and treatment, has led to increased patient survival and, consequently, to growing attention to the long-term effects of cancer therapies. Its management requires a multidisciplinary approach, in which different treatment modalities can be integrated according to the clinical and biological characteristics of the disease. Radiotherapy plays a key role, as it reduces the risk of local recurrence and disease-related mortality, thereby contributing to improved survival [1]. The aim of this study was to evaluate the acute and late toxicity of adjuvant breast radiotherapy using an ultra-hypofractionated regimen of 26 Gy in 5 fractions and to identify potential associations with patients’ clinical characteristics, irradiation technique, and dosimetric parameters. A total of 65 patients treated at the Radiation Oncology Unit of the Azienda Ospedaliero Universitaria delle Marche between October 2022 and August 2024 were analyzed. All patients underwent breast-conserving surgery and received irradiation of the residual breast without a boost or regional lymph node irradiation. The irradiation techniques used were VMAT in 42 patients, H-VMAT in 20 patients, and 3D-CRT in 3 patients. Toxicity was classified according to the CTCAE v5.0 criteria, with data collected during outpatient follow-up visits. Late toxicity was assessed at 6, 12, 18, 24, and 36 months. Associations were analyzed using statistical tests including the Mann–Whitney U test and Fisher’s exact test, with statistical significance set at p < 0.05. Acute toxicity was observed in 40 patients, predominantly in the form of skin erythema. The distribution of acute toxicity differed significantly among the three irradiation techniques, and the comparison between VMAT and H-VMAT reached statistical significance. Late toxicity was observed in 10 of 63 patients at 6 months, 4 of 57 patients at 12 months, 4 of 56 patients at 18 months, 5 of 55 patients at 24 months, and 2 of 54 patients at 36 months. The most frequent manifestation was increased breast firmness, predominantly grade 1. At 6 months, this manifestation was associated with larger CTV and PTV volumes. At subsequent follow-up assessments, no statistically significant associations were identified with the analyzed parameters. In the study population, the ultra-hypofractionated regimen of 26 Gy in 5 fractions showed good tolerability, with few late adverse events, which were predominantly mild. This study contributes to the evaluation of ultra-hypofractionated breast radiotherapy in clinical practice by documenting its good tolerability up to 36 months and providing useful insights for future investigations into potential predictors of toxicity.
Il carcinoma mammario rappresenta una delle principali patologie oncologiche a livello mondiale ed è la neoplasia più frequentemente diagnosticata nella popolazione femminile. La sua elevata incidenza, insieme al progressivo miglioramento della diagnosi precoce e dei trattamenti, ha determinato un aumento della sopravvivenza delle pazienti e, di conseguenza, una crescente attenzione verso gli effetti a lungo termine delle terapie oncologiche. La sua gestione richiede un approccio multidisciplinare, nel quale diverse modalità terapeutiche possono essere integrate sulla base delle caratteristiche cliniche e biologiche della malattia e la radioterapia riveste un ruolo fondamentale: consente infatti di ridurre il rischio di recidiva locale e la mortalità correlata alla malattia, contribuendo a migliorare la sopravvivenza [1]. L’obiettivo dello studio è valutare la tossicità acuta e tardiva della radioterapia adiuvante della mammella con schema ultra-ipofrazionato di 26 Gy in 5 frazioni e identificare eventuali associazioni con le caratteristiche cliniche delle pazienti, con la tecnica di irradiazione e con i parametri dosimetrici. Sono state analizzate 65 pazienti trattate presso la SOD di Radioterapia dell’Azienda Ospedaliero Universitaria delle Marche tra ottobre 2022 e agosto 2024. Tutte sono state sottoposte a chirurgia conservativa e trattate con l’irradiazione della mammella residua senza boost né irradiazione linfonodale. Le tecniche utilizzate sono la VMAT in 42 pazienti, l’H-VMAT in 20 e la 3D-CRT in 3. La tossicità è stata classificata secondo i criteri CTCAE v5.0 raccogliendo i dati mediante visite ambulatoriali. La valutazione tardiva è stata effettuata a 6, 12, 18, 24 e 36 mesi. L’analisi delle associazioni è stata effettuata mediante l’uso di test statistici quali il test U di Mann-Whitney e il test esatto di Fisher con soglia di significatività p < 0,05. La tossicità acuta è stata osservata in 40 pazienti, prevalentemente sotto forma di eritema cutaneo. La distribuzione della tossicità acuta differisce significativamente tra le 3 tecniche di irradiazione, e il confronto tra VMAT e H-VMAT ha raggiunto la significatività statistica. La tossicità tardiva è presente in 10 pazienti su 63 a 6 mesi, in 4 pazienti su 57 a 12 mesi, in 4 pazienti su 56 a 18 mesi, in 5 pazienti su 55 a 24 mesi e in 2 pazienti su 54 a 36 mesi. La manifestazione più frequente è l’aumento di consistenza mammaria, prevalentemente di grado 1. A 6 mesi tale manifestazione risulta associata a maggiori volumi di CTV e PTV. Nei controlli successivi non sono state rilevate associazioni statisticamente significative con i parametri analizzati. Nella casistica esaminata, lo schema ultra-ipofrazionato di 26 Gy in 5 frazioni ha mostrato una buona tollerabilità con pochi eventi tardivi prevalentemente lievi. Lo studio offre un contributo nella valutazione della radioterapia mammaria ultra-ipofrazionata nella pratica clinica, documentandone la buona tollerabilità fino a 36 mesi e fornendo indicazioni utili per futuri approfondimenti su possibili fattori predittivi della tossicità.
Radioterapia della mammella in 5 frazioni: valutazione della tossicità e dei possibili fattori predittivi
MALTEMPI, CLARISSA
2025/2026
Abstract
Breast cancer is one of the leading oncological diseases worldwide and the most frequently diagnosed malignancy among women. Its high incidence, together with the progressive improvement in early diagnosis and treatment, has led to increased patient survival and, consequently, to growing attention to the long-term effects of cancer therapies. Its management requires a multidisciplinary approach, in which different treatment modalities can be integrated according to the clinical and biological characteristics of the disease. Radiotherapy plays a key role, as it reduces the risk of local recurrence and disease-related mortality, thereby contributing to improved survival [1]. The aim of this study was to evaluate the acute and late toxicity of adjuvant breast radiotherapy using an ultra-hypofractionated regimen of 26 Gy in 5 fractions and to identify potential associations with patients’ clinical characteristics, irradiation technique, and dosimetric parameters. A total of 65 patients treated at the Radiation Oncology Unit of the Azienda Ospedaliero Universitaria delle Marche between October 2022 and August 2024 were analyzed. All patients underwent breast-conserving surgery and received irradiation of the residual breast without a boost or regional lymph node irradiation. The irradiation techniques used were VMAT in 42 patients, H-VMAT in 20 patients, and 3D-CRT in 3 patients. Toxicity was classified according to the CTCAE v5.0 criteria, with data collected during outpatient follow-up visits. Late toxicity was assessed at 6, 12, 18, 24, and 36 months. Associations were analyzed using statistical tests including the Mann–Whitney U test and Fisher’s exact test, with statistical significance set at p < 0.05. Acute toxicity was observed in 40 patients, predominantly in the form of skin erythema. The distribution of acute toxicity differed significantly among the three irradiation techniques, and the comparison between VMAT and H-VMAT reached statistical significance. Late toxicity was observed in 10 of 63 patients at 6 months, 4 of 57 patients at 12 months, 4 of 56 patients at 18 months, 5 of 55 patients at 24 months, and 2 of 54 patients at 36 months. The most frequent manifestation was increased breast firmness, predominantly grade 1. At 6 months, this manifestation was associated with larger CTV and PTV volumes. At subsequent follow-up assessments, no statistically significant associations were identified with the analyzed parameters. In the study population, the ultra-hypofractionated regimen of 26 Gy in 5 fractions showed good tolerability, with few late adverse events, which were predominantly mild. This study contributes to the evaluation of ultra-hypofractionated breast radiotherapy in clinical practice by documenting its good tolerability up to 36 months and providing useful insights for future investigations into potential predictors of toxicity.| File | Dimensione | Formato | |
|---|---|---|---|
|
TESI_DEF_PDFA.pdf
accesso aperto
Dimensione
998.43 kB
Formato
Adobe PDF
|
998.43 kB | Adobe PDF | Visualizza/Apri |
I documenti in UNITESI sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/20.500.12075/29831